Cas 159351-69-6 Everolimus RAD001 Synthesis Inhibitors MTOR Inhibitor

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Everolimus exhibits the immunosuppressive activity which is comparable to that of rapamycin. Everolimus competes with immobilized FK 506 for binding to biotinylated FKBP12 and shows the inhibitory effect on a two-way MLR performed with spleen cells from BALB/c and CBA mice with IC50 of 0.12-1.8 nM. Everolimus also shows antiangiogenic/vascular effects in VEGF-induced HUVEC proliferation with IC50 of 0.12 nM and bFGF-induced HUVEC proliferation with IC50 of 0.8 nM, respectively. A recent study shows that Everolimus shows a dose-dependent inhibitory effects on both the total cells and the stem cells from the BT474 cell line and the primary breast cancer cells with IC50 of 156 nM in total cells of primary breast cancer cells and 71 nM in total cells of BT474 cells. In addition, combination treatment with Everolimus and trastuzumab produces the significantly increased inhibition on the growth of cancer stem cells with the inhibition rate increased by more than 50 %.

Properties:

Appearance & Physical State: Off-white to light yellow powd

Density: 1.18 g/cm3

Boiling Point: 998.7ºC at 760 mmHg

Flash Point: 557.8ºC

Refractive Index: 1.548

Vapor Pressure: 0mmHg at 25°C

Related Products:

Temsirolimus; PI-103; Torin 1; PF-04691502; Apitolisib; Torin 2; BGT226; Palomid 529; Deforolimus; KU-0063794; Rapamycin; Tacrolimus

[1] Sedrani R, et al. Transplant Proc, 1998, 30(5), 2192-2194.

[2] Lane HA, et al. Clin Cancer Res, 2009, 15(5), 1612-1622.

[3] Zhu Y, et al. Tumour Biol. 2012 Apr 11. Doi: 10.1007/s13277-0